Health insurer Centene reports surprise loss on rising medical costs By Reuters

Centene (CNC) reported a surprise second-quarter adjusted loss of $0.16 per share, significantly missing the expected $0.86 profit, which led to a 14.5% premarket share decline and impacted peers. The loss was primarily attributed to a higher-than-expected Medical Cost Ratio of 93% and a downward revision in 2025 risk adjustment revenue, reflecting broader industry strains from rising medical costs, increased utilization of services, and a shift towards sicker members in government-backed insurance plans. Centene plans to seek premium increases for 2026 Obamacare plans to mitigate these ongoing cost pressures.

Analysis

Centene (CNC) reported a significant second-quarter surprise loss, posting an adjusted loss of $0.16 per share against consensus expectations for a $0.86 profit. The negative result, which triggered a 14.5% premarket stock decline and weighed on peers Elevance and Molina Healthcare, was primarily driven by a Medical Cost Ratio (MCR) of 93%, substantially worse than the 89.3% anticipated by Wall Street. This severe margin compression reflects both broad industry headwinds—including increased utilization of behavioral health and high-cost drugs—and a sicker patient mix following the expiration of pandemic-era Medicaid protections. The loss was further compounded by a downward revision to expected 2025 risk adjustment revenue under the Affordable Care Act. While management has acknowledged the performance issues and plans to seek corrective premium increases for its 2026 Obamacare plans, this action offers no near-term relief, and investors await the forthcoming 2025 earnings guidance for clarity on the company's path to restoring profitability.

Key Decisions for Investors

• Given the substantial earnings miss and severe MCR pressure at Centene, investors should monitor the upcoming conference call for the revised 2025 guidance, which will be critical for assessing if the current issues are transitory or structural.
• The cost pressures and adverse selection issues are sector-wide problems, suggesting a cautious approach towards other insurers with high exposure to government-backed plans, such as Elevance and Molina, is warranted.
• Consider that while Centene's plan to request premium increases for 2026 is a necessary step, its impact is distant and subject to regulatory approval, leaving significant uncertainty for earnings in the interim.